bioMerieux (BIM) AI Stock Analysis

• Market Cap: €11.92B
• Dividend Yield: 0.82%
• Average Volume (3M): 107.98K
• Price to Earnings (P/E): 29.7
• Beta (1Y): 0.54
• Revenue Growth: 8.28%
• EPS Growth: -8.08%
• Country: FR
• Employees: 14,147
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.00
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 122,242
• 30 Day Avg. Volume: 107,982
• PEG Ratio: -4.00
• Price to Book (P/B): 3.17
• Price to Sales (P/S): 3.20
• P/FCF Ratio: 28.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €107.80
• Price Target Upside: 6.73% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): 4.83
• Revenue Forecast (FY): €4.26B

• Rating: 68 Neutral
• Price Target: €109.00 ▲(7.92% Upside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is primarily supported by a strong, low-leverage balance sheet and generally solid profitability, tempered by softer recent growth and mixed cash conversion. Technicals are a secondary drag with the stock still below key longer-term moving averages and a negative MACD, while valuation looks demanding given the ~29.7 P/E and modest ~0.9% yield.

Positive Factors

Strong balance sheet

Consistently low leverage and a large equity base give the company durable financial flexibility to fund R&D, service contracts, or opportunistic M&A without stressing liquidity. This reduces financial risk and supports long-term investment in diagnostics capability.

Healthy margins

Sustained high gross margins reflect pricing power and differentiated products (assays, instruments). Durable margin structure supports reinvestment in innovations and aftermarket services, underpinning long-term profitability despite cyclical pressures.

Recurring consumables & contracts

A business mix weighted to consumables, maintenance and long-term hospital/lab contracts creates predictable recurring revenue and customer stickiness. This structural revenue base supports visibility, stable cash flows and resilience versus one-off sales cycles.

Negative Factors

Slowing revenue momentum

A revenue decline in 2025 signals weakening top-line momentum after prior expansion. Slower sales growth can compress operating leverage, reduce scope for reinvestment, and makes it harder to restore prior profit levels without new product wins or market share gains.

Inconsistent cash conversion

Choppy operating cash conversion and volatile free cash flow complicate capital allocation and increase execution risk. While 2024–25 FCF improved, inconsistent conversion from earnings to cash can constrain dividends, buybacks or steady R&D funding over time.

Moderating returns on equity

Falling ROE indicates the company is generating less profit per euro of equity than earlier, reflecting either slower profit growth or an expanding capital base. Lower capital efficiency can pressure shareholder returns and raise the bar for future investment.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

How the Company Makes Money

bioMérieux generates revenue primarily through the sale of its diagnostic products, which include reagents, instruments, and software. The company operates under a business model that combines direct sales and distribution partnerships to reach a global market. Key revenue streams include the sale of diagnostic kits and consumables, which are used in laboratories and healthcare facilities, as well as the provision of services such as maintenance and support for its diagnostic systems. Additionally, bioMérieux benefits from long-term contracts with hospitals and laboratories, enhancing its revenue stability. Strategic partnerships with other healthcare companies and research institutions further contribute to its earnings by expanding its product offerings and market reach. Overall, the company's focus on innovation and quality in diagnostic solutions positions it well within the growing healthcare sector.

bioMerieux Financial Statement Overview

Summary

Strong balance sheet with low leverage and a large equity base supports financial stability, while profitability remains solid. Offsetting this, revenue slipped in 2025 and profitability has cooled since the 2021 peak, with uneven cash conversion in 2022–2024 despite a 2025 free-cash-flow rebound.

Income Statement

Revenue expanded solidly from 2020–2024, but slipped slightly in 2025 (annual revenue growth -1.26%). Profitability remains good for the industry (2024 gross margin ~55.7% and net margin ~10.9%), though margins and earnings have come off the 2021 peak—net income declined from 2021 to 2024 and again in 2025. Overall, the business shows durable profitability, but recent growth and profit momentum have softened.

Balance Sheet

The balance sheet looks conservatively positioned with low leverage (debt-to-equity ~0.12–0.15 from 2021–2024) and a large equity base (equity ~€4.1–€4.2B in 2024–2025). Returns on equity were healthy but have moderated versus earlier years (about ~10% in 2024 vs. ~19% in 2021), suggesting profitability has cooled even as the capital base has grown. Overall financial risk appears low, with the main watch item being the declining return profile.

Cash Flow

Cash generation is generally supportive, with free cash flow improving meaningfully in 2024 (to ~€322M) and 2025 (to ~€453M). That said, cash flow has been choppy: free cash flow dropped sharply in 2022–2023 before rebounding, and in 2024 operating cash flow covered less than 1x of reported earnings (operating cash flow to net income ~0.59) while free cash flow was under half of earnings (~0.48), pointing to some working-capital or cash conversion pressure in that year. The 2025 step-up is a positive signal, but consistency remains the key risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.07B	3.98B	3.67B	3.59B	3.38B
Gross Profit	2.14B	2.22B	2.06B	1.96B	1.97B
EBITDA	999.60M	897.50M	701.30M	811.90M	977.80M
Net Income	397.50M	432.20M	357.60M	452.40M	601.10M
Balance Sheet
Total Assets	5.57B	5.77B	5.26B	5.19B	4.61B
Cash, Cash Equivalents and Short-Term Investments	569.80M	449.80M	352.40M	552.60M	803.50M
Total Debt	461.40M	490.70M	518.80M	505.40M	462.50M
Total Liabilities	1.47B	1.56B	1.51B	1.54B	1.44B
Stockholders Equity	4.10B	4.20B	3.75B	3.60B	3.11B
Cash Flow
Free Cash Flow	453.00M	321.50M	107.10M	188.40M	534.60M
Operating Cash Flow	788.30M	667.30M	445.40M	475.10M	824.70M
Investing Cash Flow	-461.70M	-359.80M	-488.80M	-528.10M	-307.30M
Financing Cash Flow	-155.40M	-212.60M	-122.30M	-244.20M	-140.60M

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 101.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Neutral. The current price of 101 is above the 20-day moving average (MA) of 95.02, below the 50-day MA of 102.41, and below the 200-day MA of 112.52, indicating a neutral trend. The MACD of -1.39 indicates Negative momentum. The RSI at 59.74 is Neutral, neither overbought nor oversold. The STOCH value of 86.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIM	68 Neutral	€11.92B	29.67	9.69%	0.82%	8.28%	-8.08%
SAN	66 Neutral	$98.66B	19.28	8.39%	4.77%	-9.82%	119.10%
ERF	64 Neutral	€12.37B	25.81	11.27%	0.97%	6.25%	18.93%
ALERS	55 Neutral	€233.13M	99.32	1.32%	―	12.47%	-65.87%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DIM	52 Neutral	€17.49B	67.07	6.65%	0.31%	7.72%	53.84%